GPCR Division Arrested Cells
- Use frozen cells as ordinary, cost-effective assay reagents for screening
- Decouple the labor- and time-intensive production of live cells from your screening process
- Obtain pharmacological profiles similar to those observed with growing cells
- Avoid the variability associated with cell division; get more consistent results
Figure 1 - Cost-Effective Access to High Quality, Validated GPCR Cell Lines
View our complete list of GeneBLAzer® GPCR Division arrested and dividing cell based assays.
Invitrogen acquired Division Arrest technology through our acquisition of Sentigen Holding Corp. As part of the Sentigen transaction, Invitrogen acquired the patent family which includes U.S. Patent No. 7,045,281 and Australian Patent No. 2003270073. Patent applications are currently pending in this family in the United States and a number of other countries.
For Research Use Only. Not for use in diagnostic procedures.
Screening and Profiling
- SelectScreen™ Functional GPCR Profiling Service
- Fursov, N. et al. (2005) Improving consistency of cell-based assays by using division- arrested cells. Assay Drug Dev Technol 3(1): 7–15.
- Kunapuli, P. et al. (2005) Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells. Assay Drug Dev Technol 3(1): 17–26.
- Digan, M.E. et al. (2005) Evaluation of division-arrested cells for cell-based highthroughput screening and profiling. J Biomol Screen 10(6): 615–623.
- Vasudevan, C. et al. (2005) Improving high-content-screening assay performance by using division-arrested cells. Assay & Drug Development Technologies 3(5): 515–523.